We found that NAT10 knockout and treatment with remodelin markedly inhibited HR efficiency in the breast cancer DR-GFP cell model (Figures 2G, 2H, S4F, and S4G) but not NHEJ efficiency in the EJ5-GFP cell model (Figures S6A and S6B). Here, NAT10 is linked to breast carcinoma.